LSTA logo

LISATA THERAPEUTICS INC

LSTANASDAQ
🏆 #4856 by market capUS Equity
$1.06▲ $0.01 (+1.44%)
Market closed · at close
🔔
Track LSTA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.4%
7d▲ 3.9%
14d▼ 0.5%
30d▼ 28.2%
ytd▼ 43.3%
1y▼ 60.6%
🏦Market Cap
$10M
Small Cap
📈Revenue Growth (YoY)
-83.0%
Declining
📊Gross Margin
95.0%
High
💵FCF Margin
-12323.0%
Thin
⚖️P/S Ratio
91.9x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.03 – $1.07
52-Week Range
$0.96 – $5.07
Volume (shares)
2,084
Avg Volume (shares)
—
Shares Outstanding
9.0M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$170,000
Last Q Revenue
—
P/E Ratio
-0.6
P/S Ratio
91.9x
EPS (TTM)
$-1.61
Dividend Yield
0.00%
Dilution (1yr)
+4.3%
LSTA logo

LISATA THERAPEUTICS INC

LSTA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$170K▼ −83.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
14.1%▼ −85.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$18M▼ −18.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$16M▼ −17.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
8.7M▲ +4.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$16M▼ −$116K YoY
StockOtter · stockotter.space

About LISATA THERAPEUTICS INC

Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
9 analysts
Strong Buy2
Buy4
Hold3
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.